Short answer
ICU MEDICAL INC/DE (ICUI) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $537M (down 8.9% year over year) with net income of −$39M.
Q3 2025 key financials · XBRL
- Revenue
- $537M
- −8.9% YoY · −2.2% QoQ
- Net income
- −$39M
- −234.6% YoY · −176.2% QoQ
- Operating margin
- 2.6%
- Gross margin
- 37.4%
- EPS (diluted)
- −$0.14
- +89.6% YoY · −109.8% QoQ
Source: XBRL data from the ICU MEDICAL INC/DE (ICUI) Q3 2025 10-Q on SEC EDGAR. USD.
ICU MEDICAL INC/DE Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No information on cash position, operating cash flow, or capital deployment
- No management commentary on outlook, guidance, or headwinds
Risk Factors
- Newly added risk: Sept 2025 U.S. Commerce Dept national security probe on medical imports under Section 232, potential additional tariffs on key products
- Most materially updated risk: July 31, 2025 tariff increase from 10% to 15% on imports from Costa Rica impacting supply chain costs
- Regulatory risk: Possible elimination of USMCA tariff exemptions for Mexico-manufactured goods could substantially increase tariff expenses
- Operational risk: Escalating trade tensions and retaliatory tariffs could reduce customer demand and lead to order terminations
- Financial risk: Long-term fixed-price contracts limit ability to pass increased tariff costs, threatening margins and cash flows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ICU MEDICAL INC/DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.